NeOnc Technologies Holdings, Inc. ((NTHI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NeOnc Technologies Holdings, Inc. is conducting a clinical study titled ‘An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation.’ The study aims to evaluate the safety, pharmacokinetics, and efficacy of NEO100, a perillyl alcohol, in treating patients with Grade IV glioma or recurrent primary or secondary Grade IV glioma. This research is significant as it targets a challenging condition with limited treatment options.
The intervention being tested is NEO100, administered intranasally. It is designed to be self-administered four times daily in 28-day cycles, with the goal of determining the maximum tolerated dose and assessing its efficacy in treating gliomas with IDH1 mutations.
The study is interventional, non-randomized, and follows a single-group model without masking. Its primary purpose is treatment-focused, aiming to establish the safety and efficacy of NEO100 for the specified patient group.
The study began on January 27, 2016, and is currently recruiting participants. The last update was submitted on August 6, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s timeline and ensuring transparency in its development.
This update could influence NeOnc Technologies’ stock performance positively if the results show promise, as it addresses a critical need in glioma treatment. Investors may also view the study’s progress as a sign of the company’s commitment to innovation in oncology, potentially affecting market sentiment. Competitors in the oncology sector will be watching closely, as successful outcomes could shift the competitive landscape.
The study is ongoing, with further details available on the ClinicalTrials portal.